TRK 170

Drug Profile

TRK 170

Latest Information Update: 26 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Toray
  • Class Antiulcers
  • Mechanism of Action Alpha4-beta7 integrin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Crohn's disease

Most Recent Events

  • 01 Apr 2014 Toray completes a phase II trial in Crohn's disease in Belgium, Bulgaria, Czech Republic, France, Hungary, Latvia, Netherlands, Norway, Poland, Romania, Serbia, Sweden and Ukraine (NCT01345799)
  • 27 May 2011 Phase-II clinical trials in Crohn's disease in Bulgaria, Czech Republic, Hungary, Latvia, Netherlands, Poland, Romania, Serbia and Ukraine (PO) after 27 May 2011
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top